News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “T-Cell Immunotherapy for Cancer - Pipeline Analysis”, CAR-T will soon be the next wave of drugs to reach the market
         
It is one of the emerging treatment strategies which hold a lot of promise for the unmet need in the oncology sector. CAR-T is being used on a wide array of cancer types. At present, the target of the CAR T-cell therapy is primarily hematological malignancies (leukemia and lymphoma). Pharmaceutical companies and research organizations are investing heavily in exploring the potential of CAR T-cell therapy. CAR-T therapies are expected to gain approval by 2017
 
Combining CAR T-cell therapy with other novel therapies has the potential to dramatically improve patient outcomes by attacking the multiple avenues that a cancer uses to survive.
 
Also, there are various prominent market players such as Novartis, Juno, and Kite Pharma with CD19-targeted CAR T-cell treatments in development for B-cell malignancies. Vor BioPharma, an immuno-oncology startup also plans to expand the treatment's targets in this segment. Bellicum Pharmaceuticals, Theravectys, Bluebird Bio and others have also been developing CAR-T treatments. Competitors like Cellectis, Adaptimmune, Celyad may maintain a competitive edge through its allogenic CAR T-cell technology.
 
Research Analysis and Highlights
 
The report provides an in-depth study on the current state of the T-Cell Immunotherapy industry. The report also provides a comprehensive insight about the market dynamics including the drivers, challenges, opportunities, and upcoming trends that would influence the market. It also covers the global as well as regional prevalence of major types of cancer for which T-cell immunotherapy is used. A detailed pipeline analysis of T-cell immunotherapy with a comprehensive overview of various aspects of the clinical trials in the T-cell immunotherapy market has also been provided in the report
 
Detailed information of key market players has also been included in the report to present a complete picture of the global T-cell Immunotherapy market, to enable the clients to understand the market structure and growth. In brief, the report, “T-Cell Immunotherapy for Cancer - Pipeline Analysis”, covers all the necessary aspects of the T-Cell Immunotherapy industry, providing an in-depth research and prudent analysis of the pipeline products and key therapeutic areas.
 
Some of the key highlights of the report include the following:

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM850.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm